Author: Ravi Shankar

Initial $1,000,000 USD Investment with Anticipated Follow-on Investments From a Leading Institutional Investor

Ninety-Day Commitments on Track

WINTER PARK, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) — Streamex Corp. (“Streamex” or the “Company”) (NASDAQ: STEX), a technology company building the future of the commodity markets through tokenization, today announced that an institutional investment manager has launched an investment strategy using GLDY, Streamex’s gold-backed, yield-bearing tokenized asset, as the long leg of a gold-denominated delta-neutral trade. A leading institutional investor will allocate an initial $1 million to the strategy with anticipation to scale beyond with follow on investments as the strategy demonstrates its performance. Streamex views strategies of this kind as a powerful new channel for growing GLDY assets under management. Separately, the ninety-day commitments Streamex set when it reported second quarter earnings in mid-August are on track.

Highlights

• Institutional capital deployed into a GLDY-based strategy: a leading institutional investor will allocate an initial $1,000,000 USD to an investment strategy using GLDY as its long asset. Streamex anticipates the allocation to scale beyond that with follow on investments as the strategy demonstrates its performance.
• A powerful new channel for GLDY AUM growth: the strategy, run by an institutional investment manager, uses GLDY as the long-gold leg of its trade, so as the strategy scales, GLDY assets under management grow in tandem.
• Ninety-day commitments on track: converting the first institutional allocations into GLDY was the top objective Streamex set for itself in August, and it has now been met.

Henry McPhie, Co-Founder & Chief Executive Officer of Streamex, said:

“During our second quarter earnings call, we told investors what to hold us to over the following ninety days, and converting institutional allocations into GLDY was at the top of that list. Now that happened. An institutional investment manager has launched a strategy built around GLDY, and a separate leading institutional investor has deployed an initial $1 million USD into it. As the strategy performs, that allocation can scale from the same investor. We believe that the launch of the strategy and investment anchoring it from a large outside investor brings real credibility to the platform we have built for GLDY.”

Progress Against the Ninety-Day Commitments Set in Mid-August 2026

Commitment	Status as of September 24, 2026
Convert the institutional allocations into GLDY	Met. An initial $1 million was allocated to an investment strategy that holds GLDY as its long asset. Streamex anticipates the allocation to scale beyond with follow on investments as the strategy demonstrates performance; amounts beyond the initial deployment are at the investor’s discretion.
Onboard the institutional partners as holders, not indications of interest	Met. An institutional manager acquires GLDY as capital is deployed under the strategy.
Launch initial liquidity bootstrapping for GLDC	In progress, on timeline.
Launch GLDC once initial liquidity bootstrapping is complete	Sequenced to follow completion of bootstrapping.
Complete the Equity Trust IRA integration	In progress.
Keep attesting and distributing, monthly and without interruption	Ongoing. The sixth consecutive monthly GLDY yield distribution was paid in September 2026, with reserves viewable via the Chainlink Proof of Reserves oracle.

About Streamex Corp.

Streamex Corp. (NASDAQ: STEX) is a technology and infrastructure company focused on the tokenization and digitalization of commodity real-world assets. Streamex delivers institutional-grade solutions that bridge traditional finance and blockchain-enabled markets through secure, regulated, and yield-bearing financial instruments.

For more information, visit www.streamex.com.

Important Disclosure
This press release is issued by Streamex Corp. concerning developments in its own business. It is not an offer to sell or a solicitation of an offer to buy any security, including any interest in any fund or investment strategy referenced herein, and it is not intended to advertise, promote, or solicit investment in any fund. No information contained herein should be construed as a recommendation to invest in any fund or trading or investment strategy.

Streamex is not a placement agent, distributor, solicitor, or agent for the investor referenced in this release, its manager, or any fund, and receives no compensation based on capital raised by any such fund. References to the strategy are provided solely as context for Streamex’s commercial relationship with the investor and its expected effect on GLDY assets under management. This release is not a channel for fund-related inquiries, and Streamex will not respond to or forward any such inquiries.

Capital commitment. The commitment described herein represents an indication of capital to be deployed and remains subject to execution of definitive documentation, satisfaction of conditions, and funding. There can be no assurance that it will be funded in whole or in part, or that any particular amount of GLDY will be acquired. The reference to the commitments the investor has made are provided with its consent.

Nothing in this release constitutes investment, legal, tax, or accounting advice. GLDY is offered by Streamex Ltd. pursuant to applicable exemptions from registration and is available only to eligible investors; this release does not constitute an offer of GLDY. The targeted 3.5% annualized GLDY yield is a target, is not guaranteed, and is subject to the risks of the Company’s gold leasing program, including counterparty default.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of U.S. securities laws, including statements regarding the institutional capital commitment described herein, the funding and deployment of that commitment, anticipated growth in GLDY assets under management and related management fee income, including management’s expectations regarding broader institutional adoption of GLDY, statements regarding Streamex’s progress against and expected completion of the objectives described on its second quarter 2026 earnings call, the continued payment of the 3.5% targeted annualized yield on GLDY and the continued availability of liquidity and settlement characteristics for GLDY, management’s beliefs regarding the significance of the first institutional order for the Company’s tokenization platform, and Streamex’s business strategy and future growth. There can be no assurance that the capital commitment described will be funded in whole or in part, that any particular amount of GLDY will be acquired, or that GLDY assets under management will grow by any particular amount. These statements are based on current expectations and assumptions subject to risks and uncertainties, many of which are beyond Streamex’s control, and actual results may differ materially. Factors that could cause such differences include, among others, market conditions, gold price volatility, funding rate volatility in derivatives markets, the actions and timing of third parties, including institutional allocators, custodians, trading venues, and the strategy’s manager, the Company’s ability to continue to generate and distribute the targeted yield through its gold leasing program and to maintain current liquidity and settlement characteristics for GLDY, regulatory developments, and macroeconomic factors affecting digital asset and commodity markets. A discussion of these and other factors is set forth in Streamex’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, as may be supplemented or updated by Streamex’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Streamex undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.

Contacts Streamex Press & Investor Relations
Laura Kiernan Head of Investor Relations IR@streamex.com | laura@streamex.com	Henry McPhie Chief Executive Officer, Streamex Corp. www.streamex.com | X.com/streamex

Agreement would expand the companies’ genetic testing collaboration beyond ophthalmology to a selected suite of genomic testing products through an additional U.S. reseller channel

ARLINGTON, Mass., Sept. 24, 2026 (GLOBE NEWSWIRE) — Kala Bio, Inc. (Nasdaq: KALA) (“Kala”) and Virotek Inc. (“Virotek”) today announced that they have signed a non-binding letter of intent (the “LOI”) with a U.S. DNA testing platform under which the platform would resell Virotek’s selected suite of genomic testing products. The mechanics of the commercial and economic terms are being finalized. Assuming negotiations are completed, the companies expect to name the reselling parties in the coming weeks.

The LOI follows the exclusive U.S. distribution and reseller agreement between Kala and Virotek announced on September 3, 2026. Under that agreement, Kala markets and distributes Virotek’s genetic testing and screening program in the United States while Virotek operates the laboratory infrastructure, kit supply, specimen processing, and clinical reporting. Although the initial contract with Virotek is for ophthalmology, KALA facilitated the introduction to the potential reseller and will therefore benefit economically if the deal closes, through a profit-split or commission-based structure, since Virotek will shoulder most of the logistics to fulfill orders.

For Virotek, the proposed arrangement would expand distribution of selected genetic testing products through an additional U.S. channel. For Kala, it would represent the first reseller relationship facilitated under the Virotek collaboration beyond ophthalmology. Any expansion remains subject to definitive agreements and the applicable scope of the parties’ existing agreements.

The companies believe the proposed arrangement may create an additional channel for appropriately ordered genetic testing across a range of clinical applications beyond ophthalmology. Virotek will continue to maintain responsibility for its laboratory processes, clinical reporting, quality standards, and applicable regulatory and compliance requirements.

The LOI is non-binding, except for certain limited provisions. The proposed arrangement remains subject, among other things, to finalizing the economic terms, negotiating and executing definitive agreements, and other customary conditions. There can be no assurance that definitive agreements will be reached on the contemplated terms, if at all, that the reselling parties will be named, or that the arrangement will generate revenue. Kala has not established, and this release does not contain, any revenue projection.

“This is the step that takes our genetic testing program beyond ophthalmology and into the wider market. We are still finalizing the economics, and there is no guarantee we complete them, but we believe this relationship puts Kala on a path to realizing revenue from the program. Just as important, it is a marker of what we are building: an AI- health-centred, biotech-oriented company that grows through its verticals and delivers long-term value to shareholders,” said Avi Minkowitz, Chief Executive Officer of Kala.

“This proposed arrangement expands the reach of Virotek’s clinical genomics platform through an additional commercial channel while preserving the standards that define our offering. As we broaden our commercial relationships, our priority remains clinical quality, scientific rigor and the responsible delivery of Virotek’s testing services,” said Dr. Saeid Babaei, Chairman and Chief Executive Officer of Virotek.

About Kala Bio, Inc. (NASDAQ: KALA)
KALA BIO, Inc. is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The Company’s dual strategy combines a proprietary biologics pipeline—including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates—with a scalable AI platform-as-a-service business that deploys secure, purpose-built AI solutions directly within biotech and pharmaceutical client environments.

Through its exclusive worldwide license for Younet’s Researgency AI research platform, Kala intends to serve as the biotechnology industry’s dedicated AI infrastructure partner, enabling organizations of all sizes to unlock the value of their proprietary biological data without surrendering control. Kala is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows. The Company’s focus on enterprise security, real-time performance, and seamless integration positions it at the forefront of innovation in the life sciences AI sector.

Kala believes the future of biomedical innovation is in agentic systems.

For more information, visit www.kalarx.com and Researgency.ai

About Virotek

Virotek Inc. is a U.S. precision health and clinical genomics company offering products and services to healthcare providers and organizations across the continuum of care, from preventive risk assessment and early cancer detection to personalized treatment guidance, delivered through an integrated clinical genomics platform. Virotek’s testing services are supported by its laboratory, quality, clinical reporting, and compliance infrastructure. For more information, visit Virotek.io.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategic initiative to build an AI infrastructure platform for the biotechnology industry; plans to develop and deploy the Researgency AI platform both internally and to external clients; expectations regarding the potential benefits of AI-driven analytical tools; plans to reassess historical datasets and identify new therapeutic indications; expectations regarding the AI drug discovery market and industry trends; expectations regarding the Company’s ability to generate recurring platform revenue; plans regarding potential partnerships, client deployments, or technology licensing opportunities; expectations regarding the Company’s competitive position and the differentiation of its on-premises deployment model; the potential exercise of development continuation or renewal options under the Agreement; and other statements that are not historical facts. It also includes statements regarding the proposed distribution partnership with Virotek, including the negotiation and execution of definitive agreements and the anticipated benefits and timing thereof.

The Company used words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions to identify these forward-looking statements. These statements involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance, or achievements to be materially different from those expressed or implied by such statements. Important factors that could cause such differences include, but are not limited to: risks that AI technologies may not produce expected results in drug discovery or development; risks related to the development, deployment, and performance of the Researgency platform; risks that the Company may not successfully attract or retain external platform clients; risks that the platform-as-a-service business model may not generate anticipated revenues; risks that the Company’s product candidates may not be successfully developed or commercialized; risks related to the Company’s limited cash resources and ability to continue as a going concern; risks that the third-party information contained herein was not accurate at the time it was published and/or does not accurately predict the future; risks related to the Company’s ability to raise future capital and the possibility that market conditions may limit the Company’s ability to raise capital on favorable terms; risks related to the Company’s ability to regain compliance with Nasdaq listing requirements; competition from larger, better-resourced companies including major technology and pharmaceutical companies; dependence on key personnel and third-party technology providers; the accuracy of third-party market forecasts and projections cited herein; risks that the Company may elect not to expand or continue its deployment of the Researgency platform beyond the initial term; risks that Younet may not perform its obligations under the Agreement; and other risks detailed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K as they may be revised in the Company’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and other filings with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contacts:

Avi Minkowitz
Chief Executive Officer, KALA BIO, Inc.
am@kalarx.com
www.kalarx.com | www.Researgency.ai

Dr. Saeid Babaei
Chairman and Chief Executive Officer, Virotek Inc.
info@virotek.io

BERKELEY, CA, Sept. 24, 2026 (GLOBE NEWSWIRE) — Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensor technologies today announced that the Company has received a positive decision from GMED regarding certification of its quality management system to ISO 13485. GMED is a notified body designated under the European Union Medical Device Regulation (MDR). The Company continues to work with GMED toward completion of the remaining applicable MDR conformity assessment activities for the Lumee® Oxygen Platform. Successful completion of these activities would support issuance of the applicable MDR certificate and the Company’s subsequent CE marking of the Lumee Oxygen Platform. The CE mark signifies that a product sold within the 27 EU member states meets high safety, health and environmental protection standards.

“We are pleased with the progress we have made in strengthening our quality management system, responding to GMED’s requirements and, importantly, receiving a positive decision regarding ISO 13485 certification,” said Ben Hwang, Ph.D., President of Profusa. “This represents a significant milestone for Profusa and reflects the outstanding work our team has undertaken to address GMED’s observations and advance our path toward completion of MDR conformity assessment for the Lumee Oxygen Platform.”

While the Company has made progress in its conformity assessment activities, there can be no assurance regarding the timing or outcome of GMED’s remaining assessment activities or the timing of CE marking for the Lumee Oxygen Platform.

The Lumee Oxygen Platform is designed to provide continuous, real-time monitoring of tissue oxygen levels through Profusa’s proprietary tissue-integrated biosensor technology. The platform is intended to provide clinicians with objective tissue perfusion data that may support treatment decision-making and patient monitoring.

About Profusa

Based in Berkeley, California, Profusa is a digital health company developing a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on pioneering next-generation biosensor technologies. Profusa previously announced the signing of an Option Agreement (the “Agreement”) which provides Profusa the right and option, but not the obligation, subject to satisfaction of certain conditions, to acquire G3 Vision Labs, Inc. and its subsidiaries (“G3″). Upon option exercising, the combined company is expected to operate as a public diagnostics company.

“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa, Inc. in the United States, Canada, European Union, China, Japan, South Korea, and Australia.

For more information, visit https://profusa.com.

Special Note Regarding Forward-Looking Statements

Certain statements in this press release may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa, including statements regarding the proposed acquisition of G3, and Profusa’s strategic plans. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements including, without limitation, risks related to the Company’s planned European and U.S. product launches, the risk that such product launches may not result in revenue at the levels anticipated, the risk that customer demand may be less than expected, and risks relating to the Company’s withdrawal of the Registration Statement and conducting a smaller offering of its securities. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management, are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described more fully in the Company’s public filings made by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.

Investor and Media Contact:

info@coreir.com
212-655-0924

Vancouver, BC, Sept. 24, 2026 (GLOBE NEWSWIRE) — Deep Sea Minerals Corp. (CSE: SEAS) (OTCQB: DSEAF) (FSE: X450) (“Deep Sea Minerals” or the “Company”), a subsea mineral exploration and development company focused on advancing critical mineral opportunities from the deep ocean, welcomes recent comments from U.S. Secretary of the Interior Doug Burgum regarding the advancement of deep sea mineral permitting in the United States.

On September 14, 2026, Secretary Burgum stated that deep sea mining permits could be issued within the coming months as the United States continues efforts to strengthen and diversify critical mineral supply chains. His comments follow broader U.S. initiatives to streamline offshore mineral leasing and permitting.

“We welcome the continued progress toward establishing clear and efficient regulatory pathways for responsible deep sea mineral development in the United States,” said James Deckelman, Chief Executive Officer of Deep Sea Minerals Corp. “The growing focus on offshore critical minerals reflects their potential role in strengthening U.S. critical mineral supply chains. Deep Sea Minerals remains focused on responsibly advancing its own U.S. regulatory strategy through the established NOAA process.”

The Company’s wholly owned subsidiary, American Deep Sea Minerals Corp., has submitted an application to the National Oceanic and Atmospheric Administration (“NOAA”) under the Deep Seabed Hard Mineral Resources Act of 1980 (“DSHMRA”) for an exploration license covering approximately 147,368km² within the Clarion-Clipperton Zone of the Pacific Ocean.

On May 26, 2026, NOAA determined the Company’s application to be in substantial compliance, establishing the Company’s priority of right for issuance of an exploration license with respect to its applied-for concession area under the DSHMRA framework. On July 17, 2026, the Company submitted an amended application that it believes addresses NOAA’s supplemental information requests. The application remains subject to further regulatory review, and substantial compliance does not constitute an exploration license or authorization to commence offshore activities.

The Department of the Interior’s offshore mineral framework is separate from the NOAA-administered DSHMRA process applicable to the Company’s current application.

ABOUT DEEP SEA MINERALS CORP.

Deep Sea Minerals Corp. is a subsea mineral exploration and development company focused on evaluating opportunities to support the future supply of critical minerals through the acquisition, exploration, and development of deep-sea mineral assets.

The Company’s strategy is centered on identifying jurisdictions and geological settings with potential exposure to polymetallic nodule systems, which are recognized for containing combinations of metals that may be relevant to defense, industrial manufacturing, clean energy infrastructure, advanced electronics, and artificial intelligence-related supply chains. These seabed resources represent a largely undeveloped component of the global mineral supply base and are the subject of increasing policy, scientific, and regulatory attention worldwide.

As part of this process, the Company has commenced early-stage engagement with selected governments and regulatory bodies in the Pacific Ocean region to assess potential pathways for future exploration initiatives, subject to applicable international, national, and environmental frameworks.

For further information, please see the Company’s website: https://www.deepseamineralscorp.com

SOCIAL MEDIA

Facebook: https://www.facebook.com/deepseacorp/
Instagram: https://www.instagram.com/deepseacorp
X: https://x.com/deepseacorp
LinkedIn: https://www.linkedin.com/company/deepseacorp
Youtube: https://www.youtube.com/@deepseacorp

ON BEHALF OF THE BOARD 
“James A. Deckelman”
James A. Deckelman, Chief Executive Officer

For further information, please contact:

James A. Deckelman
Chief Executive Officer

Phone: 1-281-467-1279
Email: info@deepseamineralscorp.com

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved the contents of this press release.

Forward-Looking Statements

This news release includes “forward-looking information” that is subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. Forward-looking statements may include but are not limited to Company’s plans, objectives and strategies, expected benefits of subsea mineral exploration and development, and are subject to all of the risks and uncertainties normally incident to such events. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements.

Renk Group AG: Release according to Article 40 (1) of the WpHG (the German Securities Trading Act) with the objective of Europe-wide distribution

24. Sep 2026 / 13:29 CET/CEST, transmitted by GlobeNewswire.

The issuer is solely responsible for the content of this announcement.

---

Notification of Major Holdings

1. Details of issuer

2. Reason for notification

3. Details of person subject to the notification obligation

Legal entity

4. Name(s) of shareholder(s) holding directly 3% or more voting rights, if different from details of person subject to the notification obligation

5. Date on which threshold was crossed or reached

6. Total positions

7. Details on total positions

a. Voting rights attached to shares (Sec. 33, 34 WpHG)

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG

8. Information in relation to the person subject to the notification obligation

9. In case of proxy voting according to Sec. 34 (3) WpHG

Date of general meeting

Total positions (6.) after general meeting:

10. Other useful information

Date

End of message

---

GlobeNewsWire Distribution Services include regulatory announcements, financial/corporate news and press releases.

Archive at www.globenewswire.com

---

Bang & Olufsen A/S has, pursuant to the Danish Capital Markets Act, received a major shareholder notification from UBS Group AG.

• As per 17 September 2026, UBS Group AG’s holding of shares and voting rights pursuant to section 38 of the Danish Capital Markets Act, as well as other financial instruments pursuant to section 39(2), was below 5 percent of the total share capital and voting rights in Bang & Olufsen A/S.
• As per 18 September 2026, UBS Group AG’s holding of shares and voting rights pursuant to section 38 of the Danish Capital Markets Act, as well as other financial instruments pursuant to section 39(2), was above 5 percent of the total share capital and voting rights in Bang & Olufsen A/S.
• As per 21 September 2026, UBS Group AG’s holding of shares and voting rights pursuant to section 38 of the Danish Capital Markets Act, as well as other financial instruments pursuant to section 39(2), was below 5 percent of the total share capital and voting rights in Bang & Olufsen A/S.

As of 21 September 2026, UBS Group AG held a total of 7,356,338 shares and voting rights in Bang & Olufsen A/S, corresponding to 4.993 percent of the total share capital and voting rights.

For further information, please contact:

Cristina Rønde Hefting
Sr. Director, Head of Strategy & Investor Relations
Phone: +45 4153 7303

Attachment

• BO_2618_Major shareholder announcement_UBS

Cash and cash equivalents of $7.2 million as of June 30, 2026; subsequent $5 million gross proceeds from private placement supports development and market readiness.

PETAH TIKVA, Israel, Sept. 24, 2026 (GLOBE NEWSWIRE) — TurboGen Ltd. (NASDAQ:TRBG) (TASE:TURB) (“TurboGen” or the “Company”), a developer of combined heat and power systems based on multifuel microturbines, today reports financial results for the six months ended June 30, 2026 and provides a business update. The Company reported positive shareholders’ equity of $1.6 million as of June 30, 2026.

“Our strong cash position of $7.2 million as of June 30, 2026, combined with the $5 million raised in August 2026, supports our preparations for commercialization,” said Yaron Gilboa, TurboGen’s Chief Executive Officer. “Our recent Nasdaq Capital Market (“Nasdaq”) listing is an important milestone that we believe will broaden our visibility among U.S. investors as we advance our commercial strategy. Our priorities are to prepare for initial installations, adapt our systems for scaled production, and advance commercialization in the United States and Europe.”

Business Overview

TurboGen develops compact, multi-fuel microturbine systems designed to generate electricity and heat for customers where needed.

The Company intends to serve owners and developers of office, residential, hotels and building clusters, as well as off-grid consumers, small server farms, and data centers. Its primary target markets are the United States and European Union countries with established natural gas infrastructure.

TurboGen offers two commercial models. Customers can purchase an installed system with a service contract or enter a long-term Energy-as-a-Service (“EaaS”) agreement to buy the electricity and heat generated by the system with little to no upfront cost. The Company also plans to integrate its systems with commercially available electricity and heat storage technologies to create local microgrids, supported by an energy management system that coordinates electricity and heat supplied from multiple sources.

First Half 2026 Business Highlights and Subsequent Events

●	Completed assembly of its first TR8000 model, an 80kW system designed for large buildings and micro data centers.
●	Raised $5 million in gross proceeds in an August 2026 private placement.
●	TurboGen’s ordinary shares began trading on Nasdaq on August 31, 2026.
●	First installations of our microturbine systems ranging from 32kW to 80kW expected toward the end of 2026.

First Half 2026 Financial Results

TurboGen remained a development-stage company and generated no revenue during this period. Research and development expenses increased to $1.9 million from $0.6 million for the same period in 2025, reflecting increased testing, materials and contractor costs, preparations for scale production, and share-based compensation.

Sales and marketing expenses were $281,000, compared to $203,000 for the same period in 2025, primarily reflecting higher compensation expenses.

General and administrative expenses increased to $3.1 million from $1.4 million for the same period in 2025, reflecting higher share-based compensation and professional expenses associated with the Nasdaq listing.

Operating loss increased to $5.2 million from $2.3 million for the same period last year.

Net loss narrowed 45% to $4.2 million, compared to $7.6 million for the same period in 2025. The improvement primarily reflected a $6.4 million favorable change in warrant fair-value and debt-extinguishment effects, partially offset by higher operating expenses.

Cash and cash equivalents totaled $7.2 million on June 30, 2026, compared to $3.9 million on December 31, 2025. Net cash used in operating activities was $2.7 million, compared to $1.4 million in the prior-year period. Shareholders’ equity was positive at $1.6 million as of June 30, 2026, an improvement of $4.7 million from December 31, 2025.

About TurboGen

Founded in response to technologically address the threat of climate change and the lack of grid capacity, TurboGen Ltd. (NASDAQ:TRBG) (TASE:TURB) develops combined heat and power systems based on multifuel microturbines. These microturbines are used for local electricity, energy, and heat production. To learn more, please visit: https://turbogenchp.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, TurboGen is using forward looking statement in this press release when it discusses the use cases of its products, the likelihood of success of its projects, its preparations for commercialization, its belief that listing on Nasdaq is an important milestone that will broaden our visibility among U.S. investors, advancement of its commercial strategy, its expectations for initial installations toward the end of 2026, and its priorities to adapt its systems for scaled production and advance commercialization in the United States and Europe. Because such statements deal with future events and are based on TurboGen’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of TurboGen could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2026, as amended. Copies are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

IR and Communications Contact:
IR@turbogenchp.com

New 65V digital power monitors help designers track accumulated energy data to improve system response in applications that also depend on higher levels of measurement headroom and spike protection

CHANDLER, Ariz., Sept. 24, 2026 (GLOBE NEWSWIRE) — As automotive, AI/data center, networking and industrial systems quickly migrate toward 48V power architectures to improve efficiency and support higher power demands, designers need more than visibility into instantaneous voltage and current conditions. They need systems that understand energy use over time and can respond intelligently to changing power conditions. Microchip Technology (Nasdaq: MCHP) today announced the PAC1761 and PAC1861 families of 65V energy-aware digital power monitors that combine accumulated power-measurement insights with the necessary high-voltage measurement headroom and transient spike protection capabilities to help make 48V power architectures more efficient and resilient.

The move to 48V power architectures demands that digital power monitors have an additional operational margin of up-to-65V measurement and 75V of spike protection to ensure transient survivability. The PAC1761 and PAC1861 devices add to these capabilities the intelligence to understand and react in real time to energy usage dynamics based on accumulated power measurement data.

“The industry conversation is shifting from measuring power at a single point in time to understanding and responding to energy behavior across an entire system and its lifecycle,” said Keith Pazul, vice president of Microchip’s mixed-signal linear business unit. “The PAC1761 and PAC1861 families are designed to help customers build better performing and more reliable 48V systems that can measure instantaneous conditions and understand energy consumption and availability over time. These scalable, low-power solutions reduce monitoring overhead and include pin-compatible package options that improve source flexibility while reducing design risk.”

Microchip’s digital power monitoring devices feature programmable alerts for voltage, current and power excursions, step-limit detection to identify sudden load changes, and configurable accumulated-energy thresholds that enable proactive system management based on both instantaneous and long-term power behavior.

Target applications include automotive, AI/data center, networking, industrial, server, telecom/Power over Ethernet (PoE) and 48V power distribution systems. The 12-bit PAC1761 and 16-bit PAC1861 options are available in VDFN-8 (similar to SOT23-8), VDFN-10 and MSOP-10 packages including automotive-orderable variants. Pin-compatible options can reduce redesign risk, shorten qualification cycles and give customers flexibility to move between devices as requirements, availability, cost or performance change.

Development Tools

Development support includes evaluation board EV12R33A, a Python Command Line Interface (CLI) with library, Linux^® driver and generic C library with multiple MCU code examples.

Pricing and Availability

Products in the PAC1761 and PAC1861 families are available now starting at $0.56 each in 10,000-unit quantities for the PAC1761T-3E/E3 and PAC1861T-1E/3P, both in the MSOP-10 package. The price of the evaluation board EV12R33A is $49.00. You can purchase directly from Microchip or contact a Microchip sales representative or authorized worldwide distributor.

Resources

High-res images available through Flickr or editorial contact (feel free to publish):

• Application image: www.flickr.com/photos/microchiptechnology/55488013925/sizes/o/ 
• Tool photo: www.flickr.com/photos/microchiptechnology/55487739878/sizes/o/

About Microchip Technology:
Microchip Technology Inc. is a broadline supplier of semiconductors committed to making innovative design easier through total system solutions that address critical challenges at the intersection of emerging technologies and durable end markets. Its easy-to-use development tools and comprehensive product portfolio supports customers throughout the design process, from concept to completion. Headquartered in Chandler, Arizona, Microchip offers outstanding technical support and delivers solutions across the industrial, automotive, consumer, aerospace and defense, communications and computing markets. For more information, visit the Microchip website at www.microchip.com. 

Note: The Microchip name and logo and the Microchip logo are registered trademarks of Microchip Technology Incorporated in the U.S.A. and other countries. All other trademarks mentioned herein are the property of their respective companies.

Editorial Contact:
Brian Thorsen
480-792-7182
brian.thorsen@microchip.com

Strong Preliminary Support with Approximately 88% of Votes Cast to Date on the Transaction in Favor of the Merger with Thramann Holdings

Procedural Adjournment Provides Additional Time to Vote; Meeting to Reconvene October 7, 2026, at 11:30 a.m. Eastern Time

Auddia Urges Stockholders Who Have Not Voted to Vote FOR Transaction with Thramann Holdings Today

BOULDER, Colo., Sept. 24, 2026 (GLOBE NEWSWIRE) — Auddia Inc. (NASDAQ: AUUD) (“Auddia” or the “Company”), an AI-first technology company pursuing a merger that, if completed, would form McCarthy Finney, an AI-native operating company, today announced that its Special Meeting of Stockholders (the “Special Meeting”) originally scheduled for Wednesday, September 23, 2026, was convened and immediately adjourned to October 7, 2026, at 11:30 a.m. Eastern Time. The adjournment is a procedural step intended to provide additional time for stockholders who have not yet voted to submit their proxies. It is not the result of opposition to the merger and does not alter the Board’s support for the transaction. The adjourned meeting will continue to be held virtually via a live audio webcast at www.virtualshareholdermeeting.com/AUUD2026SM.

The Company issued the following statement:

Approximately 88% of Auddia shares casting votes to date on the merger proposal have been in favor of the merger with Thramann Holdings, a level of support that demonstrates strong momentum behind the transaction. The transaction, however, can only be completed once a majority of all outstanding Auddia shares have been voted for the merger proposal. The Company currently remains short of this threshold because not enough stockholders have voted yet, not because stockholders are voting against the proposed merger. Voting activity has increased recently, reinforcing the Company’s expectation that continued outreach and additional stockholder participation will drive further progress toward reaching the required threshold before the adjourned meeting.

The Board of Directors remains firmly confident that the merger with Thramann Holdings represents the best path to long term shareholder value and believes the strong preliminary support from voters validates the strategic rationale for the combination. While the solicitation continues during this procedural adjournment, Auddia continues to execute operationally across both Auddia and the Thramann Holdings entities, particularly with respect to LT350, which is gaining increasing recognition as a compelling solution to the community resistance being faced by large datacenter deployments.

“We are encouraged that approximately 88% of the shares voted to date on the merger are in support of the transaction, demonstrating overwhelming support for the proposal,” said Jeff Thramann, Chief Executive Officer of Auddia. “With voting activity ongoing, we are confident that continued stockholder participation can move us closer to the required threshold. We continue to believe the combination with Thramann Holdings offers the most compelling path to building long term value for Auddia stockholders.”

We urge stockholders to submit their votes as soon as possible in order to realize the benefits of the transaction and protect the value of their investment.

VOTE TODAY

Stockholders of record as of the close of business on August 3, 2026, are entitled to vote at the Special Meeting. If you have already submitted your proxy, your vote remains valid and there is nothing further you need to do.

Vote today by proxy card, online or by phone.

If you have any questions, need assistance, or would like to vote by phone or email, please contact Auddia’s proxy solicitation firm, Campaign Management, toll-free at 1-844-400-3680 or via email at info@campaign-mgmt.com.Their team is available to help you vote your shares quickly and easily.

About the Merger to form McCarthy Finney (MCFN)

Auddia entered into a definitive merger agreement with Thramann Holdings, LLC on February 17, 2026. If completed, the transaction would combine Auddia with three early-stage, AI-native operating companies wholly owned by Thramann Holdings: LT350, Influence Healthcare, and Voyex. The combined company would be renamed McCarthy Finney Inc. and is expected to trade under the ticker MCFN, subject to applicable approvals and listing requirements. McCarthy Finney would operate as an AI holding company supporting LT350, Influence Healthcare, Voyex, and Auddia with AI and Web3 capabilities.

• LT350 is a distributed AI datacenter company with 14 issued patents and 3 pending patent applications covering its proprietary solar parking lot canopy infrastructure platform. The platform integrates modular battery storage and GPU cartridges into the canopy ceiling to convert the airspace of underutilized parking areas into distributed AI datacenters. LT350 aims to build a secure, low latency, cost effective, and rapidly deployable edge network while supporting local power infrastructure resilience.
• Influence Healthcare is a healthtech company leveraging AI, blockchain, and vertical integration to empower surgeons to drive adoption of value based care (VBC) to the surgical specialties. The Company’s mission is to leverage technology and value based enterprises (VBEs) to build an alternative healthcare system that minimizes the corporate practice of medicine, eliminates administrative waste, and enhances the autonomy and pay of health care providers to empower them to improve quality and return the patient physician relationship to the center of medicine.
• Voyex is a travel services platform that leverages agentic AI, an integrated fintech platform, and utilization of charter and private jet aircraft to significantly improve the travel experience. The Company aims to alleviate the leading pain points for travelers of lengthy flight delays and cancellations.

About Auddia Inc.

Auddia, through its proprietary AI platform for audio identification and classification, is reinventing not only how consumers engage with AM/FM radio, podcasts, and other audio content but also how artists and labels promote their music and gain access to mainstream radio audiences. Auddia’s Discovr Radio is the first music-promotion platform to deliver artists guaranteed exposure to radio listeners. Auddia’s flagship audio superapp, called faidr, delivers multiple industry firsts, including:

• Ad-free listening on any AM/FM radio station
• Content skipping across any AM/FM station
• One-touch skipping of entire podcast ad breaks
• Integrated artist discovery experiences

For more information, visit www.auddia.com.

Cautionary Note on Forward-Looking Statements

Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995, concerning Auddia, Thramann Holdings, and the proposed merger between Auddia and Thramann Holdings (the “Proposed Transaction”) and other matters. These forward-looking statements include, but are not limited to, express or implied statements relating to Auddia’s and Thramann Holdings’ management expectations, hopes, beliefs, intentions or strategies regarding the future including, without limitation, statements regarding: the structure, timing and completion of the proposed merger by and between Auddia and Thramann Holdings, and the expected effects, perceived benefits or opportunities of the Proposed Transaction; the combined company’s listing on Nasdaq after the closing of the Proposed Transaction; expectations regarding the structure, timing and completion of the financing needed to close the Proposed Transaction, including investment amounts from investors, timing of closing of the Proposed Transaction, expected proceed, expectations regarding the use of proceeds, and impact on ownership structure; the anticipated timing of the closing; the expected executive officers and directors of the combined company; each company’s and the combined company’s expected cash position at the closing and cash runway of the combined company following the proposed merger and any additional financing; the future operations of the combined company, including research and development activities; the nature, strategy and focus of the combined company; the development and commercial potential and potential benefits of any products and services of the combined company; the cash balance of the combined entity at closing; expectations related to the anticipated timing of the closing of the Proposed Transaction (the “Closing”); the expectations regarding the ownership structure of the combined company; the expected trading of the combined company’s stock on Nasdaq under the ticker symbol “MCFN” after the Closing; and other statements that are not historical fact.

All statements other than statements of historical fact contained in this communication are forward-looking statements. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are made based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management, concerning future developments and their potential effects. There can be no assurance that future developments affecting Auddia, Thramann Holdings, or the Proposed Transaction will be those that have been anticipated.

These forward-looking statements involve a number of risks and uncertainties, some of which are beyond Auddia’s or Thramann Holdings’ control, or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the conditions to the Closing or consummation of the Proposed Transaction are not satisfied, including the failure to timely obtain approval of the proposed merger from Auddia’s stockholders the risk that the required financing is not obtained in a timely manner, if at all; uncertainties as to the timing of the consummation of the Proposed Transaction; risks related to Auddia’s continued listing on Nasdaq until closing of the Proposed Transaction and the combined company’s ability to remain listed following the Closing; uncertainties regarding the impact any delay in the Closing would have on the anticipated cash resources of the combined company, and other events and unanticipated spending and costs that could reduce the combined company’s cash resources; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the merger agreement; the effect of the announcement or pendency of the merger on Auddia’s or Thramann Holdings’ business relationships, operating results and business generally; costs related to the merger; the risk that as a result of adjustments to the exchange ratio, Auddia’s or Thramann Holdings’ stockholders could own more or less of the combined company than is currently anticipated; risks related to the market price of Auddia’s common stock relative to the value suggested by the exchange ratio; risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance the development of its products and services; costs of the Proposed Transaction and unexpected costs, charges or expenses resulting from the Proposed Transaction; potential adverse reactions or changes to business relationships, operating results, and business generally, resulting from the announcement or completion of the Proposed Transaction.

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section titled “Risk Factors” in Auddia’s Annual Report on Form 10-K for the year ended December 31, 2025, which was originally filed with the SEC on March 6, 2026, subsequent Quarterly Reports on Form 10-Q filed with the SEC, and in other filings that Auddia makes and will make with the SEC in connection with the Proposed Transaction, including the Form S-4 and Proxy Statement described below, as well as discussions of potential risks, uncertainties, and other important factors included in other filings by Auddia from time to time. Should one or more of these risks or uncertainties materialize, or should any of Auddia’s or Thramann Holdings’ assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Neither Auddia nor Thramann Holdings undertakes or accepts any duty to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Auddia or Thramann Holdings.

No Offer or Solicitation

This communication and the information contained herein is not intended to and does not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the proposed transaction or (ii) an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.

NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.

Important Additional Information about the Proposed Transaction Will be Filed with the SEC

This communication relates to the proposed merger involving Auddia and Thramann Holdings and may be deemed to be solicitation material in respect of the proposed merger. In connection with the proposed Transaction, Auddia intends to file relevant materials with the SEC, including a registration statement on Form S-4 (the “Form S-4”) that will contain a proxy statement (the “Proxy Statement”) and prospectus. This communication is not a substitute for the Form S-4, the Proxy Statement or for any other document that Auddia may file with the SEC and/or send to Auddia’s stockholders in connection with the proposed merger. AUDDIA URGES, BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS TO READ THE FORM S-4, THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AUDDIA, THRAMANN HOLDINGS, THE PROPOSED TRANSACTION AND RELATED MATTERS.

Investors and stockholders will be able to obtain free copies of the Form S-4, the Proxy Statement and other documents filed by Auddia with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Copies of documents filed by Auddia with the SEC will also be available free of charge on Auddia’s website at www.auddia.com or by contacting Auddia Investor Relations at investors.auddiainc.com/contact. In addition, investors and stockholders should note that Auddia communicates with investors and the public through its investor-relations website at investors.auddiainc.com.

Participants in the Solicitation

Auddia, Thramann Holdings, and their respective directors and certain of their executive officers and other members of management may be deemed to be participants in the solicitation of proxies from Auddia’s stockholders in connection with the proposed transaction under the rules of the SEC. Information about Auddia’s directors and executive officers, including a description of their interests in Auddia, is included in Auddia’s most recent Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 6, 2026. Additional information regarding the persons who may be deemed participants in the proxy solicitations, including about the directors and executive officers of Thramann Holdings, and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they become available. These documents can be obtained free of charge from the sources indicated above.

Investor Relations:
Kirin Smith, President
PCG Advisory, Inc.
ksmith@pcgadvisory.com
www.pcgadvisory.com

ANN ARBOR, Mich., Sept. 24, 2026 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced a major milestone for Project Atlas, the Company’s most ambitious genetic engineering initiative to date. The Company has successfully integrated every planned Project Atlas transgene into living commercial silkworm hosts. This milestone completes the foundational Atlas Gene Library for construction of numerous unique recombinant spider silks.

This milestone represents a major breakthrough for the Company’s molecular biology research, genetic engineering, and development. With the Atlas Gene Library now assembled, the Company has entered the next stage of the program focused on developing stable homozygous breeding lines for each Atlas transgene. Project Atlas was designed for specific enhanced properties in strength, toughness, and flexibility that go far beyond the Company’s current production line of recombinant spider silk.

Establishing homozygous Atlas lines will provide the foundation for the systematic creation and evaluation of more than 200 potential genetic pairing configurations, potentially resulting in more than 200 distinct exotic fibers.

These combinations will allow researchers to systematically study how individual Atlas technologies perform together and identify the most promising configurations for future development. With more than 200 unique gene combinations, the Company will have an extensive palette of design configurations from which to engineer exotic fibers with novel and cutting-edge material properties. The objective of Project Atlas is the creation of next-generation recombinant silkworm strains with advanced properties, incorporating the complete suite of Atlas genetics.

“Completing the Atlas Gene Library is a defining milestone for Project Atlas,” said Dr. Xiaoli Zhang, Chief Scientist of Kraig Labs. “Every planned Atlas transgene has now been established in commercial silkworm hosts, giving us the complete set of genetic building blocks we envisioned when Project Atlas began. Our focus now shifts toward developing homozygous breeding lines and systematic evaluation of the more than 200 possible genetic configurations this library enables. Each step builds upon the last, bringing us closer to understanding the full potential of these technologies.”

Project Atlas is a comprehensive genetic engineering initiative capable of combining multiple advanced genetic technologies. It goes far beyond conventional transgenic development efforts that typically focus on individual genetic improvements. The Atlas Gene Library provides the foundation for evaluating how these individual technologies can be assembled into increasingly sophisticated multi-gene recombinant silkworm strains.

The Company believes Project Atlas represents one of the most ambitious genetic engineering initiatives ever undertaken anywhere. Through its Gene Library, Atlas offers more than 200 possible genetic configurations and its ultimate objective: combining the full suite of genes into a single production strain, with unprecedented and targeted material performance characteristics.

As homozygous Atlas lines are established, Kraig Labs will begin systematically creating and evaluating these genetic combinations. This deliberate approach is expected to provide critical insight into how multiple advanced genetic technologies interact and perform together. The knowledge gained through this work will guide the development of future recombinant spider silk technologies and identify the highest-value combinations for future commercial applications.

Project Atlas continues to advance alongside the Company’s expanding commercial spider silk production operations. While Kraig Labs executes its aggressive production scale-up strategy, its research and development team continues building the next generation of recombinant spider silk technologies. By advancing commercialization and innovation in parallel, the Company is building both the manufacturing capacity and scientific foundation needed to support long-term growth.

Completion of the Atlas Gene Library marks the beginning of the next phase of Project Atlas. As additional homozygous lines are established and new genetic combinations are evaluated, the Company expects Project Atlas to continue expanding the performance, versatility, and commercial potential of recombinant spider silk.

Kraig Labs believes the successful completion of the Atlas Gene Library further strengthens its leadership position in advanced biomaterials and genetic engineering, creating a foundation for continued innovation and future commercial opportunities.

The Company’s leadership in biomaterials was recently spotlighted on the cover of the March 2026 issue of National Geographic, highlighting the growing importance and predominance of our work in scaling spider silk production.

Interested persons can order a copy of National Geographic featuring Kraig Labs at https://ngsingleissues.nationalgeographic.com/natgeo-march-2026.

You can purchase a digital copy of the article directly from National Geographic at https://www.nationalgeographic.com/science/article/spider-silk-silkworm-genetic-engineering

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about recent Kraig Labs advancements, please watch the Company’s investor updates at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/

Kraig Labs Technology is built on a scientifically engineered silkworm, which incorporates key spider silk proteins to produce recombinant spider silk.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/282548de-075b-4efb-a9ae-64759bf97c83